Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Pembrolizumab in Advanced NSCLC
NCT02448303Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- May 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in non-small cell lung cancer (NSCLC), sponsored by Acerta Pharma. Started May 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02448303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448303.